Discovery of a novel RORγ antagonist with skin-restricted exposure for topical treatment of mild to moderate psoriasis

Clinical success of IL-17/IL-23 pathway biologics for the treatment of moderate to severe psoriasis suggests that targeting RORγt, a master regulator for the proliferation and function of Th17 cells, could be an effective alternative. However, oral RORγ antagonists (VTP43742, TAK828) with high syste...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Suxing, Liu, Dong, Shen, Ru, Li, Di, Hu, Qiyue, Yan, Yinfa, Sun, Jiakang, Zhang, Fengqi, Wan, Hong, Dong, Ping, Feng, Jun, Zhang, Rumin, Li, Jing, Zhang, Lianshan, Tao, Weikang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080595/
https://www.ncbi.nlm.nih.gov/pubmed/33911101
http://dx.doi.org/10.1038/s41598-021-88492-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080595/
https://www.ncbi.nlm.nih.gov/pubmed/33911101
http://dx.doi.org/10.1038/s41598-021-88492-1

Ejemplares similares